Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | WRN | Q14191 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21495021 | 1.00 | CES2 (0.35) | CES2CES1DAOWRNHSD17B2 | |
| SCHEMBL1811728 | 0.80 | — | — | |
| SCHEMBL4599794 | 0.77 | CES2 (0.34) | CES2CES1DAOWRNHSD17B2 | |
| SCHEMBL6865647 | 0.77 | ALOX5 (0.40) | DAOHSD17B2TOP2ATOP2BALDH1A1 | |
| SCHEMBL1849742 | 0.77 | GABBR2 (0.39) | DAOWRNTOP2ATOP2BGSK3B | |
| SCHEMBL7069962 | 0.77 | CES2 (0.34) | CES2CES1DAOWRNHSD17B2 | |
| SCHEMBL21495048 | 0.77 | ALOX5 (0.40) | DAOHSD17B2TOP2ATOP2BALDH1A1 | |
| SCHEMBL5319115 | 0.77 | DAO (0.33) | DAO | |
| SCHEMBL4173122 | 0.75 | — | — | |
| SCHEMBL5147505 | 0.72 | CES2 (0.36) | CES2CES1DAOWRNHSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016948-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | Università Degli Studi Di Milano - Bicocca (IT) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001024-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-01-08 | — | — | WO | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013052369-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013041468-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| EP-2400846-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2323697-A2 | IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY | Siemens Medical Solutions USA, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| EP-2155738-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010011964-A2 | IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2008145596-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2003055479-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-07-10 | — | — | WO | disclosed |